🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementDental erosion from nausea/vomiting on GLP-1 — 6 month update

Dental erosion from nausea/vomiting on GLP-1 — 6 month update

pete_RVA Thu, Dec 5, 2024 at 1:56 PM 15 replies 1,941 viewsPage 1 of 3
This thread is more than 18 months old. Information may be outdated. Consider searching for more recent discussions.
pete_RVA
Member
178
890
Dec 2024
Richmond, VA
Dec 5, 2024 at 1:56 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What I actually want to know is what distinguishes the nausea you can titrate through from the nausea that means stop.

If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

8 3mike_mod, SarahChen_PharmD, sarah.morrison and 5 others
Reply Quote Save Share Report
COA_Karl
Senior Member
2,123
8,901
Jan 2024
Pennsylvania
Dec 5, 2024 at 2:16 PM#2

This one has a reasonably settled answer, so here it is. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

7 2jim_asheville, matt_MKE, Dr.ReproEndo and 4 others
Reply Quote Save Share Report
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Dec 5, 2024 at 2:36 PM#3
COA_Karl said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

Last edited: Dec 5, 2024 at 3:36 PM
6 1FranDenver, Dr.BariatricHTX, LindaRN_retired and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Dec 5, 2024 at 2:56 PM#4
pete_RVA said:
The nausea I get is not really nausea, it is an aversion.

This matches mine closely enough to be worth saying so. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

5 0PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 2 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Dec 5, 2024 at 4:43 PM#5

Clinical perspective, offered as context rather than as advice. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

4 24BethLabQueen, ChrisMacros, KetoKyle and 1 other
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register